Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
Journal Paper/Review - Jan 1, 2021
Richardson Paul G, Goldschmidt Hartmut, Harousseau Jean-Luc, Dytfeld Dominik, Mellqvist Ulf-Henrik, Chng Wee Joo, Hou Jian, Bergsagel Peter Leif, Riva Eloisa, Leleu Xavier, Bladé Joan, Driessen Christoph, Quach Hang, Ocio Enrique M, Vesole David H, Waage Anders, Laubach Jacob, Munshi Nikhil C, Gay Francesca, Dimopoulos Meletios A, Rajkumar S Vincent, Mateos Maria-Victoria, Cook Gordon, Nahi Hareth, Harrison Simon, Sezer Orhan, Holstein Sarah, Zweegman Sonja, Usmani Saad Z, Boccadoro Mario, Hari Parameswaran, Kaiser Martin, Costa Luciano J, Beksac Meral, Maiolino Angelo, Leal da Costa Fernando, Sidana Surbhi, Jurczyszyn Artur, Facon Thierry, Durie Brian G M, Yong Kwee, Martin Thomas, Schjesvold Fredrik, Terpos Evangelos, Mikhael Joseph, Ludwig Heinz, Bahlis Nizar, Zamagni Elena, Davies Faith, San Miguel Jesús, Kumar Shaji K, Raje Noopur, van de Donk Niels, Lonial Sagar, Berdeja Jesus G, Hungria Vania, Baz Rachid, Weisel Katja, Vangsted Annette, Fonseca Rafael, Engelhardt Monika, Sonneveld Pieter, Einsele Hermann, João Cristina, Anderson Kenneth C, Hájek Roman, Lentzsch Suzanne, Kristinsson Sigurdur Y, Cavo Michele, Moreau Philippe
This Policy Review presents the International Myeloma Working Group's clinical practice recommendations for the treatment of relapsed and refractory multiple myeloma. Based on the results of phase 2 and phase 3 trials, these recommendations are proposed for the treatment of patients with relapsed and refractory disease who have received one previous line of therapy, and for patients with relapsed and refractory multiple myeloma who have received two or more previous lines of therapy. These recommendations integrate the issue of drug access in both low-income and middle-income countries and in high-income countries to help guide real-world practice and thus improve patient outcomes.